Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• dosage forms comprising a ciprofloxacin or pharmaceutically acceptable salt thereof, and celecoxib.
• Ciprofloxacin is an antibiotic which has been marketed in many countries for treatment of various bacterial infections and can be administered orally and via additional routes. It is available in salt form, for example, the hydrochloride salt, and has the structure:
• Celecoxib is a COX-2 inhibitor, taken orally, which is indicated to treat pain or inflammation associated with a variety of conditions.
• the structure of celecoxib is:
• PCT Patent Application Publication WO 2018/235082 discloses combinations of ciprofloxacin and celecoxib for treatment of a variety of motor neuron diseases, including, but not limited to, amyotrophic lateral sclerosis (ALS).
• ALS amyotrophic lateral sclerosis
• extended release compositions such as a tablet, that comprise ciprofloxacin or pharmaceutically acceptable salt thereof, and celecoxib.
• a tablet comprising celecoxib and a pharmaceutically acceptable salt of ciprofloxacin, and low viscosity hydroxypropyl methylcellulose having a viscosity of between 2 cP and 150 cP, when measured as a 2% solution in water at 20°C.
• processes for manufacture of a tablet comprising: forming granules comprising celecoxib and ciprofloxacin or pharmaceutically acceptable salt of ciprofloxacin; adding a low viscosity hydroxypropyl methylcellulose having a viscosity of less than 150 cP, when measured as a 2% solution in water at 20°C to the granules, to form a mixture; and compressing the mixture to form a tablet.
• ALS amyotrophic lateral sclerosis
• Figure 1 depicts a graph showing normalized mean plasma concentration over time after administration of ciprofloxacin and celecoxib on the 7 th day of administration to healthy volunteers, comparing administration via a combination tablet comprising ciprofloxacin and celecoxib (PrimeC) versus reference tablets (Ref).
• Extragranular In processes for formation of tablets, frequently, granules are formed comprising an active ingredient in combination with at least one excipient. A granulation process transforms fine powders into free-flowing, dust-free granules that are easy to compress. The granules can then be mixed by blending with additional excipients or active ingredients. The final blend is then filled into capsules or compressed into tablets.
• extr agranular refers to the part of the tablet that is not the granule.
• Intragranular The part of the composition that is within the granule, in a tablet composition formed through a granulation process.
• salt is a salt of an active compound, such as ciprofloxacin, which has been modified by making acid or base salts of the compounds. It refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention. These salts can be prepared in situ in the process of preparing the pharmaceutical dosage form, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt formed.
• Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, and mesylate.
• Steady State when the quantity of drug eliminated in the unit of time equals the quantity of the drug that reaches the systemic circulation in the unit of time.
• compositions comprising celecoxib and ciprofloxacin or a pharmaceutically acceptable salt of ciprofloxacin.
• compositions are provided wherein the ratio of celecoxib to ciprofloxacin or a pharmaceutically salt thereof, based on the weight of celecoxib to the weight of the ciprofloxacin free base is between 1: 1 to 1:100, optionally, 1:4,1:10, 1:25.
• Exemplary tablets described herein comprise 34 mg of celecoxib per tablet, and 340 mg of ciprofloxacin or a pharmaceutically acceptable salt of ciprofloxacin, in an amount to deliver 340 mg ciprofloxacin (for example 377.41 mg of ciprofloxacin HC1 per dosage form, or tablet which corresponds to 340 mg of ciprofloxacin free base) thereby having a celecoxib to ciprofloxacin free base ratio, by weight, of 1:10.
• compositions comprising celecoxib and ciprofloxacin or a pharmaceutically salt thereof have one, or more than one of the following dissolution characteristics: Dissolution of ciprofloxacin of less than 70%, preferably between 40% and 65% within two hours, when placed in 750 ml of 0.1N HC1, in a Type II apparatus, at 75 revolutions per minute (RPM). Dissolution of ciprofloxacin of less than 80%, preferably between 40% and 65% within two hours, when placed in 750 ml of 0.1N HC1, in a Type II apparatus, at 100 revolutions per minute (RPM) at 37°C.
• dissolution of ciprofloxacin of less than 70% preferably between 40% and 65% within two hours, when placed in 750 ml of 0.1N HC1, in a Type II apparatus, at 75 revolutions per minute (RPM).
• compositions comprise low viscosity hydroxypropyl methylcellulose (HPMC).
• HPMC is a binder and control release agent used in matrix systems of oral pharmaceutical dosage forms such as tablets.
• HPMC is an excipient that comprises a cellulose backbone having monomers that are substituted methyl groups and hydroxypropyl groups.
• HPMC The amount of substitution can determine properties of the HPMC.
• One of the properties of HPMC is its viscosity, which is typically measured as a 2% solution in water at 20°C.
• HPMC used in compositions described herein has low viscosity, which is below 150 centipoise (cP) and above 2 cP.
• HPMC used in compositions has a viscosity of between 40 and 60 cP.
• HPMC types are described below.
• Pharmacoat 603, 645, 606, and 615 are exemplary HPMC having a viscosity of less than 150 cP, and having Methoxyl: 29% (28.0%-30.0%), Hydroxypropoxyl: 10%.(7.0%-12.0%)
• Methocel E50 LV is an exemplary HPMC having a viscosity of less than 150 cP and having Methoxyl: 29% (28.0%-30.0%), Hydroxypropoxyl: 10% (7.0%- 12.0%).
• Methocel E15 Premium LV is an exemplary HPMC having a viscosity of less than 150 cP, and having Methoxyl: 29% (28.0%-30.0%), Hydroxypropoxyl: 10%
• Methocel K100 LV is an exemplary HPMC having a viscosity of less than 150 cP, and having Methoxyl: 19.0 - 24.0%, Hydroxypropoxyl: 7.0 - 12.0%, Viscosity, 2% in water at 20°C: 80 - 120 cP, Moisture, as packaged: 3.0 Max.
• the amount of HPMC present in the composition is between 3% and 10% percent, by weight of the composition.
• the amount of HPMC present in the composition is 5% by weight of the tablet core.
• the amount of HPMC present in the composition is between 4% and 15%, relative to the total weight of the active ingredients of the tablet, celecoxib and the ciprofloxacin salt.
• the amount of HPMC by weight present in the composition is between 6 and 8 percent, relative to the combined weight of the active ingredients of the tablet.
• the amount of HPMC is 7% relative to the combined weight of the active ingredients of the dosage form.
• the HPMC is present in the extragranular portion of the tablet, and preferably, the active ingredients are present in the intragranular portion of the tablet.
• contemplated herein is a tablet having intragranular components comprising ciprofloxacin and celcocoxib, a filler, a binder and optionally a wetting agent; and an extragranular composition comprising the HPMC, a filler and optionally a flowing agent and/or a lubricant.
• celecoxib and ciprofloxacin HC1 are different in that celecoxib is a very poorly soluble drug with an estimated solubility in plain water of about 4.3 mg/L at 25 °C (estimated) and ciprofloxacin HC1 is a soluble drug with a solubility in water of about 30 grams per liter. The differences in solubility are especially pronounced in acidic media.
• the compositions described herein may provide optimal therapeutic effect by being delivered through extended release of both ingredients over more than 4 hours.
• compositions described herein may be used for treatment of ALS in patients in need thereof.
• a composition may be administered once daily, twice daily, three times daily, or four times daily to a patient in need thereof.
• the administration may reduce or alleviate a symptom of ALS or prevent progression of ALS upon administration.
• the composition is preferably administered with food and water.
• Example 1A Preparation of Immediate Release (IR) Capsules Comprising Ciprofloxacin HC1 and Celecoxib
• IR capsules were prepared by mixing ciprofloxacin hydrochloride (HC1) in an amount of 377.41 mg per capsule, with celecoxib, in an amount of 34.00 mg per capsule. The mixture was filled in #0 gelatin capsules.
• Example IB Dissolution of IR Capsules
• IR capsules prepared as in Example 1A were tested for dissolution using 750 ml of 0.1N HC1, for one hour followed by addition of 250 ml phosphate buffer to form a pH 6.8 phosphate buffer, with 1% sodium lauryl sulphate.
• Conditions of the dissolution test in this example were designed to simulate administration of a capsule prepared as in example 1A to a human patient, in which the capsule would remain in the stomach acidic condition for about 1 hour, then pass into the intestine, where the pH is closer to 6.8.
• Ciprofloxacin almost fully dissolved while Celecoxib was not released after 1 hr in 0.1N HC1.
• Dissolution of both celecoxib and ciprofloxacin was rapid, after addition of 250 ml phosphate buffer to form a pH 6.8 phosphate buffer, with 1% sodium lauryl sulphate and within a few hours of administration to a human, all of the ciprofloxacin would be released.
• a profile providing a longer release time of ciprofloxacin was desired.
• Example 2A Preparation of Extended Release (ER) Tablets Comprising Ciprofloxacin HC1 and Celecoxib
• a tablet matrix composition (designated batch 08) was developed to take into account the different solubilities of the two actives, ciprofloxacin and celecoxib, and to provide a longer release time of ciprofloxacin, which would begin in the acidic conditions of the stomach, and continue while the dosage form was passed through the intestine.
• Microcrystalline cellulose USP, NF; FMC International, Cork, Ireland.
• Ciprofloxacin hydrochloride was sifted through a #16 mesh screen, and Celecoxib was sifted through a #16 mesh screen and microcrystalline cellulose/lactose sifted through a #40 mesh screen manually.
• a binder solution was prepared by weighting a quantity of sodium lauryl sulphate and Povidone, PVP K-30 which were then added to purified water while stirring, which was continued until a clear solution was obtained.
• Dry Mix The sifted material was loaded in rapid mixer granulator (10L) and dry mixed for 10 minutes using a slow impeller speed and with the chopper off.
• Granulation Binder solution were added to the dry mix and the wet mass was passed through #10 mesh screen manually.
• Blending and Lubrication Hydroxy propyl methyl cellulose (METHOCEL E 50 PRE LV), Microcrystalline cellulose (Avicel PH102), and Colloidal Silicon Dioxide (Aerosil 200) were sifted through a #40 mesh screen. Dried granules of the intragranular portion and sifted material of the extragranular portionwere then blended (Conta Blender 10L) together for 15 minutes at 15 RPM.
• Magnesium stearate was sifted through a #60 mesh screen and added to above blend and lubrication was performed for 5 minutes at 15 RPM. The final blend was compressed.
• Example 2B Dissolution of ER Tablets of Batch 08
• a dissolution test of Batch 08 was performed in 750 ml in 0.1N HC1 for 2 hours followed by transferring the dosage form to pH 6.8 Phosphate Buffer with 1% SLS, 900 mL, Type II, at 100 RPM.
• the percentage of drug release at various time points is detailed in Table 3 below.
• Example 3A Preparation of Additional Extended Release (ER) Tablets Comprising Ciprofloxacin HC1 and Celecoxib
• This example uses more soluble filler, such as lactose, in place of the extragranular filler in the Batch 08 composition, to attempt to improve the dissolution of the celecoxib.
• soluble fillers lactose
• HPMC MEMOLYMER LV
• Example 2A The general manufacturing procedures employed in Example 2A were used, with the excipients described in Table 4 below, to form Batch 36:
• batch 37 was prepared, in which was lactose was used as the extragranular filler, and lactose monohydrate was used in place of microcrystalline cellulose as the filler in the granulate.
• lactose was used as the extragranular filler
• lactose monohydrate was used in place of microcrystalline cellulose as the filler in the granulate.
• the general manufacturing procedures employed in Example 2A were used, with the excipients described in Table 5 below, to form Batch 37:
• batch 38 was prepared, in which lactose was used as the extragranular filler, and a portion of the microcrystalline cellulose in the granulate of batch 08 was substituted with lactose monohydrate.
• the general manufacturing procedures employed in Example 2A were used, with the excipients described in Table 6 below, to form Batch 38:
• Example 3B Dissolution of ER Tablets of Batch 08 versus Batch 37
• a dissolution test was performed comparing dissolution of tablets prepared from Batch 08 and from Batch 37, in 0.1N HC1 for 2 hours followed by transferring the dosage form to pH 6.8 Phosphate Buffer with 1% SLS, 900 mL, Type II, at 100 RPM.
• the percentage of drug release at various time points is detailed in Table 7 below.
• a dissolution test was performed comparing dissolution of tablets prepared from Batch 08 and from Batch 37, in 0.1N HC1 for 2 hours Type II, at 100 RPM. The percentage of drug release at various time points is detailed in Table 8 below. Dissolution was performed simultaneously on 3 tablets of each batch in a 12-unit dissolution apparatus.
• Ciprofloxacin starts going into solution in faster rate as its solubility is higher than celecoxib in 0.1N HC1. But as the solubility of Celecoxib is very low in 0.1N HC1, its drug release is minimally affected due to this phenomenon, and more affected by the presence of the soluble lactose filler that cause to faster drug release, upon transfer of the dosage form to phosphate buffer after two hours.
• Example 4A Preparation of Additional Extended Release (ER) Tablets
• the core tablet was coated with Opadry Blue, in an amount of 17.1 mg per tablet.
• lactose was used as an intragranular filler and as an extragranular filler as opposed to microcrystalline cellulose in Batch 08.
• a different HPMC polymer was also used - Methocel E15 LV.
• Batch 39B was prepared using excipients described in Table 10 below.
• the core tablet was coated with Opadry Blue, in an amount of 17.1 mg per tablet. Tablets made according to Batch 39B were similar to those of Batch 39A, with the difference that a different type of HPMC was used. Batch 40A was prepared using excipients described in Table 11 below.
• the core tablet was coated with Opadry Blue, in an amount of 17.1 mg per tablet.
• This composition was similar Batch 08, but a different HPMC polymer was used, Methocel E15 LV.
• Batch 40B was prepared using excipients described in Table 12 below.
• the core tablet was coated with Opadry Blue, in an amount of 17.1 mg per tablet.
• This composition was similar Batch 08, but a different HPMC polymer was used, Methocel E15 LV.
• Example 4B Dissolution of ER Tablets
• Example 2B showed only limited (50%) celecoxib release after 12 hours.
• the rapid release of ciprofloxacin in the acidic medium may result in partial tablet disintegration, and therefore the tablet may not be completely transferred from the acidic medium., therefore an alternate method was also used.
• compositions comprising low viscosity HPMC were effective in dissolution of ciprofloxacin to acceptable levels of less than 70%, preferably between 40% and 65% in 0.1N HC1 for 2 hours, while maintaining dissolution at levels above 80% over 10 hours in this method at 75RPM and over 6 hours at 100RPM.
• Example 6A Additional Tablet Compositions
• Batch 2D was prepared using excipients described in Table 16 below. Batch 2D represents a batch in which the amount of HPMC was 20% of the tablet weight.
• Batch 05E was prepared using excipients described in Table 17 below and represents a batch in which the amount of HPMC was 10% of the tablet weight. Additional tablet compositions were prepared in the method similar to Batch 08.
• Batch 05B was prepared using excipients described in Table 18 below.
• Batch 05B represents a batch in which the type of HPMC was Methocel KI 00 LV in an amount of 5% of the tablet weight.
• Batch 05F represents a batch in which the amount of HPMC Methocel E50LV was 5% of the tablet weight as batch 08.
• Example 6B Dissolution of ER Tablets of Batch 2D versus Batch 05E, and 05B A dissolution test was performed comparing dissolution of tablets prepared from Batches 2D, 05E, and 05B in a medium having pH of 12, at 75 RPM. The percentage of drug release at various time points, in minutes, is detailed in Table 19 below.
• compositions from Batch 05B, and 05F as batch 08 gave similar dissolution profile release of each active ingredient in pH 12 medium.
• Composition from batch 05E, having 10% by weight HPMC Methocel E 50 LV and 05B, having 5% by weight HPMC Methocel K100LV did show a promising release profile, releasing more than 40%, even 50% of actives within two hours.
• Composition of Batch 2D, in which the amount of HPMC Methocel K 100 LV was 20% of the tablet weight gave slower dissolution profile release of both active ingredient in pH 12 medium.
• Example 6C Additional tablet compositions were prepared in the method similar to Batch
• Batch 19C was prepared using excipients described in Table 20 below. Batch 19C represents a batch in which the amount of HPMC was 3% of the tablet weight.
• a dissolution test was performed to determine dissolution of tablets prepared from Batch 19C in a medium of 900 ml 0.1N HC1 for two hours, at 100 RPM.
• the percentage of drug release at various time points, in minutes, is detailed in Table 21 below.
• Example 6E Dissolution of ER Tablets in conditions comparable to “fed” conditions
• Extended Release (ER) Tablets were prepared as in example 2A, with the exception that each tablet was coated with a film coating using a hypromellose-based film, Opadry® Blue, (Opadry blue 13B 5050008 IH; Colorcon, India) in an amount of 17.10 mg/ tablet. These tablets were designated ERPC.
• a dissolution test was performed comparing dissolution of tablets prepared from Batches 08 and ERPC in a medium having pH of 4.5 using acetate buffer 1% SLS, 900 ml, at 75 RPM, USP II, with a sinker.
• the percentage of drug release at various time points, in minutes, is detailed in Table 22 below. This media was chosen to replicate administration to subjects under fed conditions.
• Example 7 Testing of tablets comprising celecoxib and ciprofloxacin HC1 in humans
• Extended Release (ER) Tablets were prepared as in example 2 A, with the exception that each tablet was coated with a film coating using a hypromellose-based film, Opadry® Blue, (Opadry blue 13B 5050008 IH; Colorcon, India) in an amount of 17.10 mg/ tablet. These tablets were used in the human trials, and were designated ERPC.
• ER Extended Release
• ERPC a fixed dose combination tablet composed of celecoxib and ciprofloxacin HC1, relative to reference products.
• the reference products were CIPRO® tablets (ciprofloxacin HC1, Bayer) co-administered with CELBREX® capsules (celecoxib, Pfizer), when administered every 12 hours for 6.5 days, for a total of 13 administrations in healthy adult males and females, under fed conditions.
• Concentration data was checked to identify pre-dose concentrations greater than 5% of Cmax for morning dose of Day 1. None of the subjects were identified with pre-dose concentration greater than 5% of Cmax for morning dose of Day 1.
• the Test Treatment consisted of a morning dose of 2 tablets of ERPC, 680 mg oral dose of ciprofloxacin and 68 mg oral dose of celecoxib in the form of 2 ERPC Tablets and an evening dose of 2 tablets of ERPC, comprising 680 mg oral dose of ciprofloxacin and 68 mg oral dose of celecoxib.
• the reference treatment consisted of a morning dose of 750 mg oral dose of ciprofloxacin of Cipro® tablets (l x 500 mg tablet and 1 x 250 mg tablet) co-administered with 200 mg oral dose of celecoxib of Celebrex® capsules (1 x 200 mg capsule), and an evening dose of 750 mg oral dose of ciprofloxacin of Cipro® tablets (l x 500 mg tablet and 1 x 250 mg tablet) co- administered with 200 mg oral dose of celecoxib of Celebrex® capsules (l x 200 mg capsule).
• the morning dose on Days 1-7 was administered to subjects at 30 minutes following the start of a normocaloric meal that was preceded by a fast of at least 10 hours.
• the evening dose on Days 1-6 was administered to subjects at 30 minutes following the start of a normo-caloric meal that was preceded by a fast of at least 2 hours.
• Pharmacokinetic parameters (mean) of ciprofloxacin and celecoxib were computed and are depicted in below in Table 23 for ciprofloxacin values and Table 24 for celecoxib values:
• Figure 1 illustrates the mean plasma concentrations of both ciprofloxacin and celecoxib in the volunteers after the seventh day of administration.
• the upper lines represent ciprofloxacin concentration after administration and the lower lines represent celecoxib.
• the ERPC group concentrations are represented by circles, and the reference group concentrations are represented by triangles.
• T m ax values for celecoxib and ciprofloxacin at Day 7 after the administration of the test treatment once the test product has been administered for a number of days and steady state is reached, the values are T m ax for celecoxib (5 hours) is within the range of between 80% and 125% of the T m ax for ciprofloxacin (4 hours). This is evident in the peaks of concentration of ciprofloxacin and celecoxib occurring relatively at the same time in Fig. 1.
• the T m ax value for celecoxib is 200% of the T m ax value of ciprofloxacin. This is evident in the peaks of concentration for the ciprofloxacin reference product occurring earlier than the peak of concentration for the celecoxib reference product.
• a tablet comprising celecoxib and ciprofloxacin or a pharmaceutically acceptable salt thereof, and low viscosity hydroxypropyl methylcellulose having a viscosity of between 2 cP and 150 cP, when measured as a 2% solution in water at 20°C.
• the pharmaceutically acceptable salt of ciprofloxacin is ciprofloxacin HC1.
• the hydroxypropyl methylcellulose has methoxyl substitution of between 28.0% and 30.0% and hydroxypropoxyl substitution of between 7.0% and 12.0%.
• the hydroxypropyl methylcellulose has methoxyl substitution of between 19.0% and 24.0%, and hydroxypropoxyl substitution of between 7.0% and 12.0%.
• the hydroxypropyl methylcellulose is present in an amount of between 3% and 10% by weight of the tablet.
• hydroxypropyl methylcellulose is present in an amount of 5% by weight of the tablet.
• the hydroxypropyl methylcellulose is present in an amount of between 4% and 15% by weight relative to the weight of the active ingredients, celecoxib and a pharmaceutically acceptable salt of ciprofloxacin, in the tablet.
• the hydroxypropyl methylcellulose is present in an amount of between 6% and 8% by weight relative to the weight of the active ingredients.
• the tablet comprises an extragranular component and an intragranular component, wherein the hydroxypropyl methylcellulose is present in the extragranular component.
• the celecoxib and the pharmaceutically acceptable salt of ciprofloxacin are present in the intragranular component.
• the tablet further comprises a filler, selected from the group consisting of soluble, non soluble and a mixture of soluble and non soluble fillers.
• the filler is selected from the group consisting of: dicalcium phosphate, starch, pregelatinized starch, powdered cellulose, microcrystalline cellulose, mannitol, sucrose, sorbitol, and lactose.
• the filler is microcrystalline cellulose, lactose, mannitol, or a combination thereof.
• the low viscosity hydroxypropyl methylcellulose has a viscosity of 50 cP, when measured as a 2% solution in water at 20°C.
• the ratio of weight of celecoxib to the weight of the ciprofloxacin free base is between 1:1 to 1:100.
• the ratio of weight of celecoxib to the weight of the ciprofloxacin free base is 1:10-1:25.
• the ratio of weight of celecoxib to the weight of the ciprofloxacin free base is 1:10.
• the dissolution of ciprofloxacin is less than 70% and greater than 40%, within two hours, when placed in 750 ml of 0.1N HC1, in a Type II apparatus, at 75 revolutions per minute (RPM), and wherein the dissolution of ciprofloxacin is a total of at least 80% within 6 hours when placed in 750 ml of 0.1N HC1, in a Type II apparatus, at 75 RPM, 37 °C then after two hours, medium is modified to form phosphate buffer at pH of 6.8, comprising 1% SLS.
• RPM revolutions per minute
• the dissolution of celecoxib is less than 80% within 6 hours and at least 80% within 12 hours when placed in 750 ml of 0.1N HC1, in a Type II apparatus, at 75 RPM, 37°C then after two hours, medium is modified to form phosphate buffer at pH of 6.8, comprising 1% SLS.
• more than 45% of both ciprofloxacin and celecoxib is released at 3 hours, and less than 90% is released at 6 hours, when placed in 750 ml of 0.1N HC1, in a Type II apparatus, at 75 RPM, 37°C then after two hours, medium is modified to form phosphate buffer at pH of 6.8, comprising 1% SLS.
• the Tmax for celecoxib in the subject’s serum is within the range of between 80% and 125% of the Tmax for ciprofloxacin in the subject’s serum.
• a process for manufacture of the tablet comprising: forming granules comprising celecoxib and ciprofloxacin or a pharmaceutically acceptable salt thereof; adding a low viscosity hydroxypropyl methylcellulose having a viscosity of less than 150 cP, when measured as a 2% solution in water at 20°C to the granules, to form a mixture; and compressing the mixture to form a tablet.
• ALS amyotrophic lateral sclerosis

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85982158

Family Applications (1)

Country Status (9)

Citations (1)

Family Cites Families (2)

• 2022
  • 2022-10-18 JP JP2024523514A patent/JP7857044B2/ja active Active
  • 2022-10-18 AU AU2022370513A patent/AU2022370513B2/en active Active
  • 2022-10-18 EP EP22883107.9A patent/EP4419099A4/en active Pending
  • 2022-10-18 CA CA3235348A patent/CA3235348A1/en active Pending
  • 2022-10-18 IL IL312274A patent/IL312274A/en unknown
  • 2022-10-18 US US18/047,289 patent/US12097185B2/en active Active
  • 2022-10-18 WO PCT/IL2022/051096 patent/WO2023067592A1/en not_active Ceased
  • 2022-10-18 KR KR1020247016529A patent/KR20240090519A/ko active Pending
  • 2022-10-18 CN CN202280081257.7A patent/CN118369097A/zh active Pending

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events